Table 1 Characteristics of the patients
Characteristics | Patients (n = 33) |
|---|---|
Median age (years), n (%) | 63 (45–82) |
< 70 | 26 (78.8%) |
≥ 70 | 7 (21.2%) |
Sex, n (%) | |
Male | 8 (24.2%) |
Female | 25 (75.8%) |
Smoking status, n (%) | |
Non-smoker | 31 (93.9%) |
Smoker | 2 (6.1%) |
Clinical stage a, n (%) | |
IVA | 6 (18.2%) |
IVB | 27 (81.8%) |
ECOG PS, n (%) | |
0 | 0 (0.0%) |
1 | 33 (100.0%) |
EGFR mutation, n (%) | |
Del 19 | 14 (42.4%) |
L858R | 17 (51.5%) |
Other a | 2 (6.1%) |
Brain metastasis, n (%) | 15 (46.5%) |
No. Brain metastasis, n (%) | n = 15 |
Single | 6 (40%) |
Multiple | 9 (60%) |
Location of Brain metastasis, n (%) | n = 15 |
Cerebellum | 1 (6.7%) |
Cerebellum, Cerebrum | 5 (33.3%) |
Cerebrum | 9 (60%) |
Oligo-metastatic, n (%) | n = 15 |
Single | 5 (33.3%) |
Multiple | 2 (13.3%) |
Leptomeningeal metastasis, n (%) | 2 (13.3%) |
Symptomatic brain metastasis, n (%) | 5 (33.3%) |
Treatment of brain metastasis, n (%) | n = 15 |
Surgery | 0 |
Radiotherapy | 13 (86.7%) |
Treatment, n (%) | |
Sequential afatinib followed by ramucirumab | 11 (33.3%) |
Upfront combination | 22 (66.7%) |
Response, n (%) | |
CR and PR | 33 (100.00%) |
SD | 0 (0.00%) |
Progressive disease, n (%) | |
Yes | 5 (15.2%) |
No | 28 (84.8%) |